YARDLEY, Pa., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced the commencement of a proposed underwritten public offering of shares of its common stock. All of the shares of common stock will be offered by Optinose. Optinose expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the total number of shares of common stock.

Optinose intends to use the net proceeds of the offering for working capital and general corporate purposes, including the commercialization of XHANCE, the clinical development of XHANCE for a follow?on indication for the treatment of chronic sinusitis and the clinical development of OPN-019 for the treatment of COVID-19.

Credit Suisse Securities (USA) LLC will act as sole bookrunner for the proposed offering.

About Optinose

Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat and allergy specialists.